Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what’s next for Oramed:
Josh Hexter, Oramed’s COO, spoke with BioTuesdays.com about the conclusion of the Phase IIb study, and about what’s next for Oramed: